Home › Metastatic Cancer › Florida › Miami
Pag-aaral pangklinika para sa Metastatic Cancer sa Miami, FL
Isang pag-aaral para sa Metastatic Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Miami. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Nagre-recruitPhase 2
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Nagre-recruitPhase 3
- Research Site, Miami
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Nagre-recruitPhase 2
- Sylvester Comprehensive Cancer Center, Miami
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Nagre-recruitPhase 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Nagre-recruitPhase 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Nagre-recruitPhase 1/2
- Sylvester Comprehensive Cancer Center - Miami, Miami
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- University of Miami, Miami
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Miami Cancer Institute at Baptist Health, Inc., Miami
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
Nagre-recruitPhase 1
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Nagre-recruitPhase 3
- University Of Miami-SCCC-Miami, Miami
- University of Miami_SCCC - Kendall, Miami
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Nagre-recruitPhase 3
- Research Site, Miami
- Research Site, Miami
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Nagre-recruitPhase 1
- Sylvester Comprehensive Cancer Center, Miami
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Nagre-recruitPhase 3
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nagre-recruitPhase 1/2
- University of Miami; Sylvester Cancer Center, Miami
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Nagre-recruitPhase 2/3
- Sylvester Comprehensive Cancer Center, Miami
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Nagre-recruitPhase 2/3
- Sylvester Comprehensive Cancer Center, Miami
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Nagre-recruitPhase 1
- Sylvester Comprehensive Cancer Center, Miami
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Nagre-recruitPhase 1
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Nagre-recruitPhase 3
- University of Miami, Miami
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Miami
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Nagre-recruitPhase 3
- Miami Cancer Institute, Miami
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1
- University of Miami, Miami
Pag-aaral para sa Metastatic Cancer sa ibang lungsod
- Houston, TX104 pag-aaral
- New York City, NY93 pag-aaral
- Nashville, TN70 pag-aaral
- Boston, MA63 pag-aaral
- Los Angeles, CA57 pag-aaral
- St. Louis, MO54 pag-aaral
- Arlington, VA53 pag-aaral
- Philadelphia, PA46 pag-aaral
- Chicago, IL45 pag-aaral
- San Antonio, TX44 pag-aaral
- Washington, DC43 pag-aaral
- Dallas, TX42 pag-aaral
Iba pang pag-aaral sa Miami
- Kanser sa Suso42 pag-aaral
- Kanser (lahat ng uri)36 pag-aaral
- Non-Small Cell Lung Cancer31 pag-aaral
- Kanser sa Prostate27 pag-aaral
- Obesity27 pag-aaral
- Acute Myeloid Leukemia24 pag-aaral
- Overweight23 pag-aaral
- Kanser sa Ovary23 pag-aaral
- Ulcerative Colitis21 pag-aaral
- Multiple Myeloma21 pag-aaral
- Sakit ni Alzheimer20 pag-aaral
- Kanser sa Baga20 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.